Acasti Pharma Inc. (ACST)’s Financial Results Comparing With Immunic Inc. (NASDAQ:IMUX)

This is therefore a contrasting of the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership in Acasti Pharma Inc. (NASDAQ:ACST) and Immunic Inc. (NASDAQ:IMUX). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acasti Pharma Inc. 1 0.00 N/A -1.22 0.00
Immunic Inc. 13 0.00 N/A -34.26 0.00

In table 1 we can see Acasti Pharma Inc. and Immunic Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Acasti Pharma Inc. 0.00% 0% 0%
Immunic Inc. 0.00% -235.3% -182.3%

Analyst Recommendations

Acasti Pharma Inc. and Immunic Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acasti Pharma Inc. 0 0 1 3.00
Immunic Inc. 0 0 1 3.00

The consensus target price of Acasti Pharma Inc. is $7.75, with potential upside of 262.15%. On the other hand, Immunic Inc.’s potential upside is 178.36% and its consensus target price is $40. Based on the analysts view we can conclude, Acasti Pharma Inc. is looking more favorable than Immunic Inc.

Institutional and Insider Ownership

Institutional investors owned 4.02% of Acasti Pharma Inc. shares and 1.6% of Immunic Inc. shares. Acasti Pharma Inc.’s share owned by insiders are 13.28%. On the other hand, insiders owned about 0.3% of Immunic Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acasti Pharma Inc. 2.99% 107.76% 181.87% 129.52% 338.18% 189.7%
Immunic Inc. 1.94% 21.1% 2.94% 71.52% -95.65% 83.31%

For the past year Acasti Pharma Inc. was more bullish than Immunic Inc.

Summary

Acasti Pharma Inc. beats on 5 of the 7 factors Immunic Inc.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.